

# Stephen M Stahl

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5523834/publications.pdf>

Version: 2024-02-01

132  
papers

7,320  
citations

71061

41  
h-index

56687

83  
g-index

233  
all docs

233  
docs citations

233  
times ranked

5811  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dementia-related psychosis and the potential role for pimavanserin. <i>CNS Spectrums</i> , 2022, 27, 7-15.	0.7	8
2	Polypharmacy- Purpose, Benefits and Limitations. <i>Current Medicinal Chemistry</i> , 2022, 29, 5606-5614.	1.2	4
3	REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial. <i>American Journal of Psychiatry</i> , 2022, 179, 122-131.	4.0	44
4	The effect of first- and second-generation antipsychotics on brain morphology in schizophrenia: A systematic review of longitudinal magnetic resonance studies with a randomized allocation to treatment arms. <i>Journal of Psychopharmacology</i> , 2022, 36, 428-438.	2.0	2
5	Mental energy: plausible neurological mechanisms and emerging research on the effects of natural dietary compounds. <i>Nutritional Neuroscience</i> , 2021, 24, 850-864.	1.5	5
6	Precision and personalized assessment, diagnosis and treatment in psychiatry. <i>CNS Spectrums</i> , 2021, 26, 326-332.	0.7	8
7	How and when to treat the most common adverse effects of antipsychotics: Expert review from research to clinical practice. <i>Acta Psychiatrica Scandinavica</i> , 2021, 143, 172-180.	2.2	14
8	Early response to trazodone once-a-day in major depressive disorder: review of the clinical data and putative mechanism for faster onset of action. <i>CNS Spectrums</i> , 2021, 26, 232-242.	0.7	8
9	REL-1017 (Esmethadone) Increases Circulating BDNF Levels in Healthy Subjects of a Phase 1 Clinical Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 671859.	1.6	17
10	Response to the Letter to the Editor "Psychiatry's undeclared identity crisis in a changing world" by Richard Skaff. <i>CNS Spectrums</i> , 2021, , 1-2.	0.7	0
11	Novel challenges to psychiatry from a changing world. <i>CNS Spectrums</i> , 2021, 26, 3-4.	0.7	2
12	Psychopharmacology and ethnicity: A comparative study on Senegalese and Italian men. <i>World Journal of Biological Psychiatry</i> , 2020, 21, 300-307.	1.3	4
13	Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies. <i>CNS Spectrums</i> , 2020, 25, 502-510.	0.7	178
14	Pharmacologic Treatment of Mixed States. <i>Psychiatric Clinics of North America</i> , 2020, 43, 167-186.	0.7	5
15	The relevance of COVID-19 pandemic to psychiatry. <i>World Psychiatry</i> , 2020, 19, 261-261.	4.8	91
16	New Medications for Neuropsychiatric Disorders. <i>Psychiatric Clinics of North America</i> , 2020, 43, 399-413.	0.7	9
17	Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532090575.	1.2	193
18	Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity. <i>CNS Spectrums</i> , 2019, 24, 461-466.	0.7	34

#	ARTICLE	IF	CITATIONS
19	Placebo response rate is ruining drug development in psychiatry: why is this happening and what can we do about it?. <i>Acta Psychiatrica Scandinavica</i> , 2019, 139, 105-107.	2.2	9
20	Mixed mood states: Baffled, bewildered, befuddled and bemused. <i>Bipolar Disorders</i> , 2019, 21, 560-561.	1.1	7
21	Expert Consensus on Screening and Assessment of Cognition in Psychiatry. <i>CNS Spectrums</i> , 2019, 24, 154-162.	0.7	18
22	Conditions of life and death of psychiatric patients in France during World War II: euthanasia or collateral casualties?. <i>CNS Spectrums</i> , 2018, 23, 170-175.	0.7	2
23	Evil, terrorism, and psychiatry. <i>CNS Spectrums</i> , 2018, 23, 117-118.	0.7	2
24	Serotonin and Love. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 99-101.	0.7	5
25	Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus. <i>CNS Spectrums</i> , 2018, 23, 402-413.	0.7	8
26	Mixed-up about how to diagnose and treat mixed features in major depressive episodes. <i>CNS Spectrums</i> , 2017, 22, 111-115.	0.7	16
27	Guidelines for the recognition and management of mixed depression. <i>CNS Spectrums</i> , 2017, 22, 203-219.	0.7	97
28	Flibanserin "the female Viagra". <i>International Journal of Psychiatry in Clinical Practice</i> , 2017, 21, 259-265.	1.2	4
29	Drug information update. Unconventional treatment strategies for schizophrenia: Polypharmacy and heroic dosing. <i>BJPsych Bulletin</i> , 2017, 41, 164-168.	0.7	7
30	Hypoactive Sexual Desire Disorder. <i>Mayo Clinic Proceedings</i> , 2017, 92, 114-128.	1.4	158
31	Inverse agonists "What do they mean for psychiatry?". <i>European Neuropsychopharmacology</i> , 2017, 27, 87-90.	0.3	14
32	Does a "whiff" of mania in a major depressive episode shift treatment from a classical antidepressant to an atypical/second-generation antipsychotic?. <i>Bipolar Disorders</i> , 2017, 19, 595-596.	1.1	5
33	Ciprofloxacin and Clozapine: A Potentially Fatal but Underappreciated Interaction. <i>Case Reports in Psychiatry</i> , 2016, 2016, 1-7.	0.2	10
34	Psychopharmacology of Persistent Violence and Aggression. <i>Psychiatric Clinics of North America</i> , 2016, 39, 541-556.	0.7	28
35	Major Depressive Disorder: Understanding the Significance of Residual Symptoms and Balancing Efficacy with Tolerability. <i>American Journal of Medicine</i> , 2015, 128, S1-S15.	0.6	61
36	A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. <i>European Neuropsychopharmacology</i> , 2015, 25, 2318-2325.	0.3	135

#	ARTICLE	IF	CITATIONS
37	California State Hospital Violence Assessment and Treatment (Cal-VAT) guidelines. <i>CNS Spectrums</i> , 2014, 19, 449-465.	0.7	30
38	Modulating the serotonin system in the treatment of major depressive disorder. <i>CNS Spectrums</i> , 2014, 19, 54-68.	0.7	41
39	Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. <i>CNS Spectrums</i> , 2014, 19, 439-448.	0.7	33
40	A proposal for an updated neuropsychopharmacological nomenclature. <i>European Neuropsychopharmacology</i> , 2014, 24, 1005-1014.	0.3	83
41	Mechanism of action of agomelatine: a novel antidepressant exploiting synergy between monoaminergic and melatonergic properties. <i>CNS Spectrums</i> , 2014, 19, 207-212.	0.7	191
42	Pharmacotherapy of cognitive deficits in schizophrenia. <i>CNS Spectrums</i> , 2014, 19, 142-156.	0.7	17
43	Long-acting injectable antipsychotics: shall the last be first?. <i>CNS Spectrums</i> , 2014, 19, 3-5.	0.7	66
44	Nuevas guías para el uso de la polifarmacia antipsicótica. <i>Revista De Psiquiatría Y Salud Mental</i> , 2013, 6, 97-100.	1.0	29
45	Emerging guidelines for the use of antipsychotic polypharmacy. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2013, 6, 97-100.	0.2	9
46	The tyranny of the majority and the interchangeability of drugs. <i>Acta Psychiatrica Scandinavica</i> , 2013, 127, 4-5.	2.2	2
47	“Meta-guidelines” for the management of patients with schizophrenia. <i>CNS Spectrums</i> , 2013, 18, 150-162.	0.7	61
48	The diverse therapeutic actions of pregabalin: is a single mechanism responsible for several pharmacological activities?. <i>Trends in Pharmacological Sciences</i> , 2013, 34, 332-339.	4.0	251
49	Translating from neuroscience to psychiatry (and back translating from psychiatry to neuroscience). <i>Acta Psychiatrica Scandinavica</i> , 2013, 128, 103-104.	2.2	1
50	The last Diagnostic and Statistical Manual (DSM): replacing our symptom-based diagnoses with a brain circuit-based classification of mental illnesses. <i>CNS Spectrums</i> , 2013, 18, 65-68.	0.7	24
51	Off-label prescribing: best practice or malpractice?. <i>CNS Spectrums</i> , 2013, 18, 1-4.	0.7	18
52	Controversies in treating bipolar depression. <i>CNS Spectrums</i> , 2013, 18, 175-176.	0.7	0
53	Serotonergic Drugs for Depression and Beyond. <i>Current Drug Targets</i> , 2013, 14, 578-585.	1.0	246
54	Effectiveness of Lurasidone for Patients With Schizophrenia Following 6 Weeks of Acute Treatment With Lurasidone, Olanzapine, or Placebo. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 507-515.	1.1	60

#	ARTICLE	IF	CITATIONS
55	A Horse of a Different Color: How Formulation Influences Medication Effects. CNS Spectrums, 2012, 17, 63-69.	0.7	5
56	Optimizing Outcomes in Schizophrenia: Long-acting Depots and Long-term Treatment. CNS Spectrums, 2012, 17, 10-21.	0.7	14
57	A plan for mental illness. Nature, 2012, 483, 269-269.	13.7	64
58	Antipsychotic polypharmacy: never say never, but never say always. Acta Psychiatrica Scandinavica, 2012, 125, 349-351.	2.2	33
59	Treatment Strategies for Dosing the Second Generation Antipsychotics. CNS Neuroscience and Therapeutics, 2011, 17, 110-117.	1.9	30
60	Ziprasidone Hydrochloride: What Role in the Management of Schizophrenia?. Journal of Central Nervous System Disease, 2011, 3, JCNDS.S4138.	0.7	13
61	Multifunctional Pharmacology of Flibanserin: Possible Mechanism of Therapeutic Action in Hypoactive Sexual Desire Disorder. Journal of Sexual Medicine, 2011, 8, 15-27.	0.3	256
62	Case Studies: Stahl's Essential Psychopharmacology. , 2011, , .		31
63	Efficacy and Safety of Agomelatine in the Treatment of Major Depressive Disorder. Journal of Clinical Psychopharmacology, 2010, 30, 135-144.	0.7	98
64	Antipsychotic Drug Development. Current Topics in Behavioral Neurosciences, 2010, 4, 123-139.	0.8	22
65	A Post Hoc Analysis of Negative Symptoms and Psychosocial Function in Patients With Schizophrenia. Journal of Clinical Psychopharmacology, 2010, 30, 425-430.	0.7	25
66	Enhancing Outcomes from Major Depression: Using Antidepressant Combination Therapies with Multifunctional Pharmacologic Mechanisms from the Initiation of Treatment. CNS Spectrums, 2010, 15, 79-94.	0.7	34
67	How to dose a psychotropic drug: beyond therapeutic drug monitoring to genotyping the patient. Acta Psychiatrica Scandinavica, 2010, 122, 440-441.	2.2	171
68	Fooling Mother Nature: Epigenetics and Novel Treatments for Psychiatric Disorders. CNS Spectrums, 2010, 15, 358-366.	0.7	12
69	Psychiatric Stress Testing: Novel Strategy for Translational Psychopharmacology. Neuropsychopharmacology, 2010, 35, 1413-1414.	2.8	14
70	Agomelatine in the Treatment of Major Depressive Disorder. Journal of Clinical Psychiatry, 2010, 71, 616-626.	1.1	245
71	Applying the Principles of Adult Learning to the Teaching of Psychopharmacology: Overview and Finding the Focus. CNS Spectrums, 2009, 14, 179-182.	0.7	7
72	Applying the Principles of Adult Learning to the Teaching of Psychopharmacology: Storyboarding a Presentation and the Rule of Small Multiples. CNS Spectrums, 2009, 14, 288-294.	0.7	4

#	ARTICLE	IF	CITATIONS
73	Crisis in Army Psychopharmacology and Mental Health Care at Fort Hood. <i>CNS Spectrums</i> , 2009, 14, 677-684.	0.7	5
74	Fibromyalgia's pathways and neurotransmitters. <i>Human Psychopharmacology</i> , 2009, 24, S11-7.	0.7	43
75	Why psychiatrists should not ignore pain in their patients' focus on fibromyalgia?. <i>Human Psychopharmacology</i> , 2009, 24, S1-2.	0.7	1
76	Building a Better Antipsychotic: Receptor Targets for the Treatment of Multiple Symptom Dimensions of Schizophrenia. <i>Neurotherapeutics</i> , 2009, 6, 78-85.	2.1	78
77	Multifunctional Drugs: A Novel Concept for Psychopharmacology. <i>CNS Spectrums</i> , 2009, 14, 71-73.	0.7	52
78	Mechanism of Action of Trazodone: A Multifunctional Drug. <i>CNS Spectrums</i> , 2009, 14, 536-546.	0.7	357
79	Applying the Principles of Adult Learning to the Teaching of Psychopharmacology: Audience Response Systems. <i>CNS Spectrums</i> , 2009, 14, 412-414.	0.7	4
80	Monoamine Oxidase Inhibitors: A Modern Guide to an Unrequited Class of Antidepressants. <i>CNS Spectrums</i> , 2008, 13, 855-871.	0.7	126
81	Selective Histamine H <sub>1</sub> Antagonism: Novel Hypnotic and Pharmacologic Actions Challenge Classical Notions of Antihistamines. <i>CNS Spectrums</i> , 2008, 13, 1027-1038.	0.7	228
82	Personalized Medicine, Pharmacogenomics, and the Practice of Psychiatry: On the Threshold of Predictive Therapeutics in Psychopharmacology?. <i>CNS Spectrums</i> , 2008, 13, 115-118.	0.7	15
83	Do Dopamine Partial Agonists Have Partial Efficacy as Antipsychotics?. <i>CNS Spectrums</i> , 2008, 13, 279-282.	0.7	19
84	The Potential Role of a Corticotropin-Releasing Factor Receptor-1 Antagonist in Psychiatric Disorders. <i>CNS Spectrums</i> , 2008, 13, 467-483.	0.7	21
85	Novel Therapeutics for Depression: L-methylfolate as a Trimonoamine Modulator and Antidepressant-Augmenting Agent. <i>CNS Spectrums</i> , 2007, 12, 739-744.	0.7	66
86	Overview of Trends in Modern Psychopharmacology. <i>CNS Spectrums</i> , 2007, 12, 103-105.	0.7	2
87	Beyond the Dopamine Hypothesis to the NMDA Glutamate Receptor Hypofunction Hypothesis of Schizophrenia. <i>CNS Spectrums</i> , 2007, 12, 265-268.	0.7	79
88	Analysis of the Rate of Improvement of Specific Psychic and Somatic Symptoms of General Anxiety Disorder During Long-Term Treatment with Venlafaxine ER. <i>CNS Spectrums</i> , 2007, 12, 703-711.	0.7	19
89	The Genetics of Schizophrenia Converge Upon the NMDA Glutamate Receptor. <i>CNS Spectrums</i> , 2007, 12, 583-588.	0.7	14
90	Novel Therapeutics for Schizophrenia: Targeting Glycine Modulation of NMDA Glutamate Receptors. <i>CNS Spectrums</i> , 2007, 12, 423-427.	0.7	21

#	ARTICLE	IF	CITATIONS
91	Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism. <i>International Journal of Neuropsychopharmacology</i> , 2007, 10, 575-8.	1.0	27
92	Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder. <i>Current Medical Research and Opinion</i> , 2007, 23, 2815-2822.	0.9	33
93	Finding what you are not looking for: Strategies for developing novel treatments in psychiatry. <i>NeuroRx</i> , 2006, 3, 3-9.	6.0	18
94	High-Cost Use of Second-Generation Antipsychotics Under California's Medicaid Program. <i>Psychiatric Services</i> , 2006, 57, 127-129.	1.1	50
95	SNRIs: The Pharmacology, Clinical Efficacy, and Tolerability in Comparison with Other Classes of Antidepressants. <i>CNS Spectrums</i> , 2005, 10, 732-747.	0.7	409
96	Antidepressant Treatment of Psychotic Major Depression: Potential Role of the $\alpha_1$ Receptor. <i>CNS Spectrums</i> , 2005, 10, 319-323.	0.7	53
97	Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease. <i>Current Medical Research and Opinion</i> , 2004, 20, 517-524.	0.9	39
98	Selectivity of SSRIs: individualising patient care through rational treatment choices. <i>International Journal of Psychiatry in Clinical Practice</i> , 2004, 8, 3-10.	1.2	15
99	A successful antipsychotic combination trial. Quo Vadis?. <i>Acta Psychiatrica Scandinavica</i> , 2004, 110, 241-242.	2.2	12
100	Understanding pain in depression. <i>Human Psychopharmacology</i> , 2004, 19, S9-S13.	0.7	90
101	Focus on Antipsychotic polypharmacy: evidence-based prescribing or prescribing-based evidence?. <i>International Journal of Neuropsychopharmacology</i> , 2004, 7, 113-116.	1.0	30
102	Atypical Antipsychotics: Matching Receptor Profile to Individual Patient's Clinical Profile. <i>CNS Spectrums</i> , 2004, 9, 6-14.	0.7	77
103	A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2004, 6, 159-166.	0.6	361
104	At Long Last, Long-Lasting Psychiatric Medications. <i>Journal of Clinical Psychiatry</i> , 2003, 64, 355-356.	1.1	6
105	Escitalopram in the Treatment of Panic Disorder. <i>Journal of Clinical Psychiatry</i> , 2003, 64, 1322-1327.	1.1	121
106	Antidepressants and somatic symptoms: therapeutic actions are expanding beyond affective spectrum disorders to functional somatic syndromes. <i>Journal of Clinical Psychiatry</i> , 2003, 64, 745-6.	1.1	16
107	Differences in mechanism of action between current and future antidepressants. <i>Journal of Clinical Psychiatry</i> , 2003, 64 Suppl 13, 13-7.	1.1	13
108	The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. <i>Journal of Clinical Psychiatry</i> , 2003, 64 Suppl 19, 6-12.	1.1	37

#	ARTICLE	IF	CITATIONS
109	Effects of Reboxetine on Anxiety, Agitation, and Insomnia: Results of a Pooled Evaluation of Randomized Clinical Trials. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 388-392.	0.7	30
110	The Psychopharmacology of Energy and Fatigue. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 7-8.	1.1	160
111	Antipsychotic Polypharmacy: Squandering Precious Resources?. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 93-94.	1.1	53
112	Does Depression Hurt?. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 273-274.	1.1	85
113	Mirror, Mirror on the Wall, Which Enantiomer Is Fairest of Them All?. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 656-657.	1.1	6
114	Does Evidence From Clinical Trials in Psychopharmacology Apply in Clinical Practice?. <i>Journal of Clinical Psychiatry</i> , 2001, 62, 6-7.	1.1	72
115	The Psychopharmacology of Sex, Part 1: Neurotransmitters and the 3 Phases of the Human Sexual Response. <i>Journal of Clinical Psychiatry</i> , 2001, 62, 80-81.	1.1	38
116	Fibromyalgia: The Enigma and the Stigma. <i>Journal of Clinical Psychiatry</i> , 2001, 62, 501-502.	1.1	6
117	Gut Feelings About Irritable Bowel Syndrome. <i>Journal of Clinical Psychiatry</i> , 2001, 62, 590-591.	1.1	8
118	Antipsychotic Polypharmacy, Part 1: Therapeutic Option or Dirty Little Secret?. <i>Journal of Clinical Psychiatry</i> , 1999, 60, 425-426.	1.1	114
119	Antipsychotic Polypharmacy, Part 2: Tips on Use and Misuse. <i>Journal of Clinical Psychiatry</i> , 1999, 60, 506-507.	1.1	33
120	Mechanism of action of serotonin selective reuptake inhibitors. <i>Journal of Affective Disorders</i> , 1998, 51, 215-235.	2.0	435
121	Sleep electroencephalographic response to muscarinic and serotonin <sub>1A</sub> receptor probes in patients with major depression and in normal controls. <i>Biological Psychiatry</i> , 1998, 44, 21-33.	0.7	18
122	Effectiveness of ipsapirone, a 5-HT <sub>1A</sub> partial agonist, in major depressive disorder: support for the role of 5-HT <sub>1A</sub> receptors in the mechanism of action of serotonergic antidepressants. <i>International Journal of Neuropsychopharmacology</i> , 1998, 1, 11-18.	1.0	31
123	Using Secondary Binding Properties to Select a Not So Selective Serotonin Reuptake Inhibitor. <i>Journal of Clinical Psychiatry</i> , 1998, 59, 642-643.	1.1	22
124	Mirtazapine: An Antidepressant with Noradrenergic and Specific Serotonergic Effects. <i>Pharmacotherapy</i> , 1997, 17, 10-21.	1.2	137
125	Nefazodone and the serotonin receptor modulators: a new member of a unique class of antidepressant agents. <i>International Review of Psychiatry</i> , 1995, 7, 29-39.	1.4	5
126	Biochemical pharmacology of serotonin receptor subtypes: hypotheses for clinical applications of selective serotonin ligands. <i>International Review of Psychiatry</i> , 1995, 7, 55-67.	1.4	6



#	ARTICLE	IF	CITATIONS
127	Targeting serotonin receptor subtypes as a strategy for the discovery of novel treatments in psychiatry. <i>International Review of Psychiatry</i> , 1995, 7, 3-4.	1.4	0
128	Pharmacology: Policy Implications Of New Psychiatric Drugs. <i>Health Affairs</i> , 1992, 11, 157-163.	2.5	1
129	Progressive myelopathy due to extramedullary hematopoiesis: Case report and review of the literature. <i>Annals of Neurology</i> , 1979, 5, 485-489.	2.8	22
130	Molecular and Cellular Biology Research in Psychiatry. , 0, , 29-58.		0
131	Evidence-based pharmacotherapy of major depressive disorder. , 0, , 53-72.		0
132	Evidence-based pharmacotherapy of panic disorder. , 0, , 73-89.		0